Thermo Fisher Finalizes PPD Acquisition
Thermo Fisher Scientific (Waltham, Massachusetts, USA) has announced the acquisition of global clinical research and laboratory service provider, PPD (Wilmington, North Carolina, USA). The acquisition was first announced in April, with Thermo Fisher agreeing to purchase PPD for $47.50 per share, a total of $17.4 billion, plus the assumption of around $3.5 billion of net debt.
Speaking back in April, David Simmons, Chairman and Chief Executive Officer, PPD, said, “Thermo Fisher is a world‑class company with a very similar culture and values and will provide a great foundation for our colleagues to continue to deliver for our customers and to develop their own skills and careers.”
PPD has more than 26,000 employees operating across 50 countries, and it produced revenue of $4.7 billion in 2020. Following the transaction, PPD has now become part of Thermo Fisher’s Laboratory Products and Services Segment.
“We are very excited to officially welcome our PPD colleagues to Thermo Fisher Scientific,” said Thermo Fisher Chairman, President, and CEO Marc N. Casper. “Expanding our value proposition for our biotech and pharmaceutical customers with the addition of PPD’s leading clinical research services advances our work in bringing life-changing therapies to market, benefitting patients around the world.”
For more information, please visit: www.thermofisher.com
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
